FindTrial
Sign In

Study on the effect of risk warning mode on trastuzumab/pertuzumab bone marrow suppression

Study on the effect of risk warning mode on trastuzumab/pertuzumab bone marrow suppression

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500109096
Enrollment
Unknown
Registered
2025-09-11
Start date
2025-08-05
Completion date
Unknown
Last updated
2025-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

Observation group:NA

Sponsors

Meishan City Peoples Hospital
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with HER2-positive breast cancer who received targeted therapy with trastuzumab/pertuzumab.

Exclusion criteria

Exclusion criteria: 1.Male; 2.Admission blood routine indicated myelosuppression; 3.Female and over 65 years old.

Design outcomes

Primary

MeasureTime frame
White blood cell count;Neutrophil count;—

Secondary

MeasureTime frame
Hemoglobin;Platelet count;—

Countries

China

Contacts

Public ContactFengdie Wang

Meishan City Peoples Hospital

986942589@qq.com+86 13778854543

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026